Vaxart Inc (VXRT)

$0.32 0.00 (N/A)
Market Cap 97.49M
Revenue (ttm) 28.70M
Net Income (ttm) -66.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -233.28%
Debt to Equity Ratio 0.00
Volume 11,568,300
Avg Vol 5,416,006
Day's Range N/A - N/A
Shares Out 228.31M
Stochastic %K 7%
Beta 1.14
Analysts Strong Sell
Price Target $4.67

Company Profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Season...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 550 3500
Fax: 650 871 8580
Website: vaxart.com
Address:
310 Utah Avenue, Suite 150, South San Francisco, United States
Terry_CA3
Terry_CA3 Aug. 5 at 12:07 AM
$VXRT This stock has given me a couple grey hairs
4 · Reply
AnilDK79
AnilDK79 Aug. 5 at 12:06 AM
$VXRT the covid market for pfizer and moderna is still over $5B combined for vaccine sales. the % of Americans getting covid vaccines is less than half of flu. and yet covid has a higher infection and spreading rate. safety concerns, side effects, pricing and availability all impact people’s decisions to get the covid vaccine. even in the 65+ group, it is estimated that 70% get a flu shot while only 30% get covid shot. there is a Lot of room for growth with a safe effective product with limited side effects and more reasonably priced. and easy to receive (no dr appt needed). Just need the product to work and fingers cross they didnt bungle it by going with low dose for P2B
1 · Reply
Garza759ify_YF
Garza759ify_YF Aug. 4 at 11:54 PM
$VXRT
0 · Reply
SuperCummings
SuperCummings Aug. 4 at 11:42 PM
$VXRT Rmb VX22 and its potent entities? If a vaccine leveraging highly potent VX22 antibody successfully navigates clinical trials & achieves commercialization, its market value would be estimated between $2 billion - $5 billion annually in peak global revenue. Because VX22 is a broadly neutralizing human monoclonal antibody discovered in 2025 that targets a highly conserved "weak spot" across 75% of norovirus strains, its ultimate commercial value depends on how it is utilized. It could either be used directly as a therapeutic passive immunization product or integrated as a structural blueprint to design next-generation preventative vaccines. Economic value of a commercialized norovirus vaccine utilizing this discovery is broken down below.Market Size and Financial ValueGlobal Peak Revenue: Estimated at $2B-$5B annually. No norovirus vaccine has historically cleared FDA approval, meaning the first to market will capture an untapped, highly lucrative multi-billion dollar market.
1 · Reply
SuperCummings
SuperCummings Aug. 4 at 10:03 PM
$VXRT After all these years, Cummings is still around… He’s definitely with us onboard this slow moving boat to Pluto… lol 💪🤭
0 · Reply
Byson2
Byson2 Aug. 4 at 9:10 PM
$VXRT what date is earnings
4 · Reply
Philthdawg
Philthdawg Aug. 4 at 8:28 PM
$VXRT I suffer now, so I can prosper later. Like if you resonate with this statement.
4 · Reply
PatrickKane88
PatrickKane88 Aug. 4 at 8:14 PM
$VXRT This has all the makings of a sustained rally folks
4 · Reply
Terry_CA3
Terry_CA3 Aug. 4 at 8:14 PM
$VXRT
2 · Reply
PatrickKane88
PatrickKane88 Aug. 4 at 7:55 PM
$VXRT folks this move gets us $1 to $2 range
0 · Reply
Latest News on VXRT
No data available.
Terry_CA3
Terry_CA3 Aug. 5 at 12:07 AM
$VXRT This stock has given me a couple grey hairs
4 · Reply
AnilDK79
AnilDK79 Aug. 5 at 12:06 AM
$VXRT the covid market for pfizer and moderna is still over $5B combined for vaccine sales. the % of Americans getting covid vaccines is less than half of flu. and yet covid has a higher infection and spreading rate. safety concerns, side effects, pricing and availability all impact people’s decisions to get the covid vaccine. even in the 65+ group, it is estimated that 70% get a flu shot while only 30% get covid shot. there is a Lot of room for growth with a safe effective product with limited side effects and more reasonably priced. and easy to receive (no dr appt needed). Just need the product to work and fingers cross they didnt bungle it by going with low dose for P2B
1 · Reply
Garza759ify_YF
Garza759ify_YF Aug. 4 at 11:54 PM
$VXRT
0 · Reply
SuperCummings
SuperCummings Aug. 4 at 11:42 PM
$VXRT Rmb VX22 and its potent entities? If a vaccine leveraging highly potent VX22 antibody successfully navigates clinical trials & achieves commercialization, its market value would be estimated between $2 billion - $5 billion annually in peak global revenue. Because VX22 is a broadly neutralizing human monoclonal antibody discovered in 2025 that targets a highly conserved "weak spot" across 75% of norovirus strains, its ultimate commercial value depends on how it is utilized. It could either be used directly as a therapeutic passive immunization product or integrated as a structural blueprint to design next-generation preventative vaccines. Economic value of a commercialized norovirus vaccine utilizing this discovery is broken down below.Market Size and Financial ValueGlobal Peak Revenue: Estimated at $2B-$5B annually. No norovirus vaccine has historically cleared FDA approval, meaning the first to market will capture an untapped, highly lucrative multi-billion dollar market.
1 · Reply
SuperCummings
SuperCummings Aug. 4 at 10:03 PM
$VXRT After all these years, Cummings is still around… He’s definitely with us onboard this slow moving boat to Pluto… lol 💪🤭
0 · Reply
Byson2
Byson2 Aug. 4 at 9:10 PM
$VXRT what date is earnings
4 · Reply
Philthdawg
Philthdawg Aug. 4 at 8:28 PM
$VXRT I suffer now, so I can prosper later. Like if you resonate with this statement.
4 · Reply
PatrickKane88
PatrickKane88 Aug. 4 at 8:14 PM
$VXRT This has all the makings of a sustained rally folks
4 · Reply
Terry_CA3
Terry_CA3 Aug. 4 at 8:14 PM
$VXRT
2 · Reply
PatrickKane88
PatrickKane88 Aug. 4 at 7:55 PM
$VXRT folks this move gets us $1 to $2 range
0 · Reply
Joe_Mussia
Joe_Mussia Aug. 4 at 7:25 PM
$VXRT 60¢? I want $60
1 · Reply
Tycho11261
Tycho11261 Aug. 4 at 6:15 PM
$VXRT looks good to me!🔥🔥🔥 Is the veil about to fall, FINALLY?
1 · Reply
Mucosal_Immunity
Mucosal_Immunity Aug. 4 at 5:53 PM
$VXRT OKay, don't let it go to .80 'cause Lo will sell shares for half of the price. Okay, It's a joke... because everything about this fckkn company is a joke! 😜
1 · Reply
Joe_Mussia
Joe_Mussia Aug. 4 at 5:43 PM
$VXRT
0 · Reply
franklin2025
franklin2025 Aug. 4 at 4:59 PM
$VXRT KEEP ACCUMULATING!!!
0 · Reply
Terry_CA3
Terry_CA3 Aug. 4 at 4:49 PM
$VXRT 🙄
2 · Reply
WEN_PLUTO_BONES
WEN_PLUTO_BONES Aug. 4 at 4:47 PM
$VXRT In short, historical data suggest Vaxart’s oral platform can deliver ~1.5–2+ fold mucosal sIgA rises in roughly half of subjects (where mRNA is usually weak) and ~3.5-fold higher CD8+ T-cell responses in direct comparisons. This is what matters the most to me personally..😁😁
1 · Reply
WEN_PLUTO_BONES
WEN_PLUTO_BONES Aug. 4 at 4:41 PM
$VXRT Why the next couple of months is realistic • Immunogenicity and mucosal assays (IgA, neutralizing antibodies, T-cell data, etc.) typically require additional lab work after the clinical follow-up ends. These analyses often take several weeks to a few months once the database is locked. • In many vaccine trials, companies release a safety topline first and then follow with more detailed immunogenicity results relatively soon afterward (sometimes within 1–3 months). This is what I am interested in. We will mop the floor with significant increased fold rise of IgA, T-Cells and Mucosal homing/ sIgA over mRNA. At least that’s what i’m hoping for. Durability/longevity. 😉
0 · Reply
WEN_PLUTO_BONES
WEN_PLUTO_BONES Aug. 4 at 4:13 PM
$VXRT Covid positive results = cash infusion and future royalties. Results will derisk the platform. Potential Partners will be lurking 👀 to jump in for Norovirus. Potential bidding war because we hold all the cards . Then we can do an updated P2B for Flu with the new constructs. By then we should be able to do the study on our own without dilution or cash runway issues. Not to mention, Flu should be an easy transition because of the platform and previous successful results. Hell, they might allow us to go right to P3. I’ll be right here.
2 · Reply
Garza759ify_YF
Garza759ify_YF Aug. 4 at 4:08 PM
$VXRT Does this mean buyout for VXRT?
0 · Reply
VaxartWillPrevail
VaxartWillPrevail Aug. 4 at 4:00 PM
$VXRT ya know, I’d stop talking shit about Lo and the company if they let it sit above $0.80 for awhile
2 · Reply
PatrickKane88
PatrickKane88 Aug. 4 at 3:53 PM
$VXRT Vaxart may run right through August and September with a few minor pullbacks
0 · Reply